Yea Christopher 4

What Happened

• Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals (KALV), had 3,750 restricted stock units (RSUs) settle into 3,750 shares on May 21, 2026. Those shares were issued for no cash consideration.
• On May 22, 2026, he sold 2,358 of those shares in an open-market transaction at $26.78 per share, generating $63,158 in gross proceeds. The sale was a sell-to-cover to satisfy tax withholding obligations (not a discretionary sale).

Key Details

• Transaction dates: RSU settlement/exercise-conversion on 2026-05-21; open-market sale on 2026-05-22 at $26.78 per share.
• Proceeds from sale: $63,158 (2,358 shares × $26.78).
• Shares retained from this settlement: 3,750 received − 2,358 sold = 1,392 shares remaining from this vesting (filing does not state total company-wide holdings).
• Footnotes: RSUs represent the contingent right to receive one share upon settlement for no consideration (F1). The sale was to cover tax withholding via a “sell-to-cover” (F2). Vesting schedule: 1/16th each quarterly anniversary starting May 21, 2025 (F3).
• Filing timeliness: Form 4 filed 2026-05-26 reporting transactions dated 5/21–5/22; filing appears timely.

Context

• This was a routine RSU settlement followed by a sell-to-cover tax withholding. The derivative activity reflects RSUs converting to shares (no cash cost); part of those shares were sold immediately to satisfy taxes rather than as a discretionary investment decision.
• Such routine tax-related sales are common after equity awards vest and do not, by themselves, imply a change in insider sentiment.